CryoCath’s Arctic Front, which is used for the treatment of paroxysmal atrial fibrillation (PAF), is a unique cryoablation balloon catheter that allows physicians to safely and effectively isolate all four pulmonary veins in the treatment of PAF. Arctic Front will be exclusively distributed in Hong Kong by Pacific Medical.
Jan Keltjens, president and CEO of CryoCath, said: “We are extremely proud to see Arctic Front expand into new markets beyond Europe, first in Australia, and now in Hong Kong. With our rapidly growing body of clinical evidence, we are confident that our Arctic Front system will continue to broaden its user base.”